Evolution of Movement Disorders in Patients With CLN2-Batten Disease Treated With Enzyme Replacement Therapy
Open Access
- 13 August 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (3) , e209615
Abstract
Neuronal ceroid lipofuscinosis type 2 (CLN2-disease) is an inherited childhood-onset neurodegenerative condition, with classical early features of speech delay, epilepsy, myoclonus, ataxia, and motor regression. This study aimed to better characterize the spectrum of movement disorders in CLN2-disease in a cohort of children receiving enzyme replacement therapy (ERT). A cohort of 18 children attending a single center for treatment with cerliponase alfa ERT was systematically assessed using a standardized structured history and a double-scored, video-recorded examination using the Unified Batten Disease Rating Scale (UBDRS) and Abnormal Involuntary Movement Scale. Noncanonical movement disorders are common: while ataxia (89%) and myoclonus (83%) were near-universal, spasticity and dystonia were experienced by over half (61% each), with children having a median of 4 distinct movement disorder phenotypes. This progression was stereotyped with initial ataxia/myoclonus, then hyperkinesia/spasticity, and later hypokinesia. ERT slows progression of movement disorders, as measured by the UBDRS physical subscale, with 1.45 points-per-month progression before diagnosis and 0.44 points-per-month while on treatment (p = 0.019). Movement disorders are a core feature of CLN2-disease and follow a typical pattern of progression which is slowed by ERT. Identifying and treating movement disorders should become standard, especially given increased patient survival.Keywords
This publication has 13 references indexed in Scilit:
- The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sampleEuropean Journal of Paediatric Neurology, 2022
- Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort studyThe Lancet Child & Adolescent Health, 2018
- Study of Intraventricular Cerliponase Alfa for CLN2 DiseaseNew England Journal of Medicine, 2018
- Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosisMolecular Genetics and Metabolism, 2015
- New nomenclature and classification scheme for the neuronal ceroid lipofuscinosesNeurology, 2012
- Movement Disorder in Ataxia-TelangiectasiaJournal of Child Neurology, 2012
- Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)Neurology, 2011
- Neurological deterioration in late infantile neuronal ceroid lipofuscinosisNeurology, 2007
- Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients with CLN2 mutationsAmerican Journal of Medical Genetics, 2002
- Abnormal Involuntary Movements in Neuroleptic-Naive Children and AdolescentsThe Canadian Journal of Psychiatry, 1999